| __timestamp | Incyte Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 17986000 |
| Thursday, January 1, 2015 | 196614000 | 32480000 |
| Friday, January 1, 2016 | 303251000 | 68081000 |
| Sunday, January 1, 2017 | 366406000 | 169906000 |
| Monday, January 1, 2018 | 434407000 | 248932000 |
| Tuesday, January 1, 2019 | 468711000 | 354100000 |
| Wednesday, January 1, 2020 | 516922000 | 433300000 |
| Friday, January 1, 2021 | 739560000 | 583300000 |
| Saturday, January 1, 2022 | 1002140000 | 752700000 |
| Sunday, January 1, 2023 | 1161300000 | 887600000 |
| Monday, January 1, 2024 | 1242157000 | 1007200000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, understanding financial trends is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Incyte Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Incyte's SG&A expenses surged by approximately 600%, peaking at $1.16 billion in 2023. In contrast, Neurocrine's expenses grew by nearly 4,800%, reaching $888 million in the same year.
These trends highlight the strategic financial decisions shaping the biotech landscape, offering investors a glimpse into each company's operational priorities.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared